Exchange: AMEX Industry: Biotechnology
-1.08% $11.90
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 127.27 mill |
EPS: | -4.84 |
P/E: | -2.46 |
Earnings Date: | Mar 31, 2024 |
SharesOutstanding: | 10.69 mill |
Avg Daily Volume: | 0.289 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.46 | sector: PE 12.30 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -2.46 | industry: PE -5.55 |
DISCOUNTED CASH FLOW VALUE |
---|
$3.48 (-70.78%) $-8.42 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 11.02 - 12.78 ( +/- 7.42%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-20 | White Mark K. | Buy | 1 990 | Common Stock |
2023-11-20 | Mccarthy Reid | Buy | 0 | Common Stock |
2023-11-20 | Hoffman Michael B | Buy | 163 880 | Common Stock |
2023-11-20 | Maccecchini Maria-luisa | Buy | 40 970 | Common Stock |
2023-11-20 | Hagopian Henry Iii | Buy | 820 | Common Stock |
INSIDER POWER |
---|
89.74 |
Last 98 transactions |
Buy: 4 567 241 | Sell: 3 252 094 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $11.90 (-1.08% ) |
Volume | 0.249 mill |
Avg. Vol. | 0.289 mill |
% of Avg. Vol | 86.23 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.